Clinical utility of methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction (PCR) assays beyond respiratory infections

Haley M Noeldner; Zachary J Bliek; Nephi E Jones; Ryan D Prusa; Melissa S Wilkinson; Amanda M Bushman; Rossana Rosa

doi:10.1017/ash.2022.256

Clinical utility of methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction (PCR) assays beyond respiratory infections

Antimicrob Steward Healthc Epidemiol. 2022 Jun 30;2(1):e108. doi: 10.1017/ash.2022.256. eCollection 2022.

Authors

Haley M Noeldner¹, Zachary J Bliek², Nephi E Jones², Ryan D Prusa², Melissa S Wilkinson³, Amanda M Bushman¹, Rossana Rosa^{3

4}

Affiliations

¹ Department of Pharmacy, UnityPoint Health-Des Moines, Des Moines, Iowa.
² Podiatry Service, Department of Surgery, Iowa Methodist Medical Center, Des Moines, Iowa.
³ Department of Medicine, University of Iowa-Des Moines Campus, Des Moines, Iowa.
⁴ Infectious Diseases Service, UnityPoint Health-Des Moines, Des Moines, Iowa (Present affiliations: Department of Pharmacy, Riverwood Healthcare Center, Aitkin, Mnnesota [H.M.N.] and Department of Quality and Patient Safety, Jackson Health System, Miami, Florida [R.R.]).

Abstract

We estimated the predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal polymerase chain reaction (PCR) for blood, bone, and soft-tissue cultures. The specificities were 88.8%, 88.5%, and 92.7% for all cultures, blood cultures, and bone and soft-tissue cultures respectively, and the negative predictive values were 99.3%, 99.8%, and 92.7% respectively.